Clinical trials
Inflammatory Breast Cancer clinical trials
Below are recruiting inflammatory breast cancer clinical trials, each written for real people, not researchers. We’re tracking 322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07739485RecruitingPhase 1/Phase 2
Oral paclitaxel before surgery for triple-negative breast cancer
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
Guiyang, GuizhouAges 18–70 - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT07034976Recruiting
Radiofrequency treatment for menopause symptoms in breast cancer survivors
This trial tests a non-surgical radiofrequency treatment, combined with pelvic floor exercises, to help with vaginal dryness and other menopause symptoms in breast cancer survivors. It may be an option if you are free of cancer and have bothersome vaginal dryness.
Madrid, MadridAges 18–75 - NCT07666555RecruitingPhase 2
Culmerciclib rechallenge for HR+ HER2- breast cancer
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
ShanghaiAges 18–75 - NCT04215003RecruitingPhase 1/Phase 2
Study breast cancer treatment guided by tumor pathway tests
This trial tests new treatment given before surgery for certain stage IIb–IIIc breast cancers. It uses results from your tumor to guide the treatment plan and aims to improve how well the therapy works before the operation.
Shanghai, Please SelectAges 18–70 - NCT06738654Recruiting
Robot-assisted scarless breast-conserving surgery for breast cancer
This trial uses a robotic arm through the armpit to remove breast cancer while leaving no visible scar on the chest. It is for women with early-stage breast cancer who want to keep their breast and avoid a scar.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT05190094RecruitingPhase 2
Test blood-based laser scan to guide first-line breast cancer treatment
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
BlidaAges 18 years+ - NCT04817540RecruitingPhase 2
Testing anti-HER2 treatment for HER2-enriched early breast cancer
This trial tests an anti-HER2 medicine in people whose breast cancer is classified as “HER2-enriched” using a special lab test (PAM50). It aims to see whether this treatment can help prevent or control cancer that cannot be fully removed by surgery.
SeoulAges 19 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT04019678Recruiting
Breast cancer study after chemotherapy with small underarm node spread
This study looks at whether it’s safe and effective to avoid removing many underarm lymph nodes in some people who, after chemotherapy, still seem to have only tiny (“micro”) cancer deposits in the sentinel lymph node. It may help reduce treatment side effects while keeping cancer control.
Rozzano, MIAges 18–75 - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT05911958RecruitingPhase 2
Study drug before surgery for HER2-low, HR-positive breast cancer
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
Zhengzhou, HenanAges 18–70 - NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06878625RecruitingPhase 2
Trop-2 drug combo for advanced triple-negative breast cancer
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07525869Recruiting
Pegfilgrastim to prevent low white blood cells in triple-negative breast cancer
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
Seoul, Seodaemun-guAges 19–70 - NCT06016387RecruitingPhase 2
Drug combo with radiation for HER2+ breast cancer spread to spinal lining
This trial tests a combination of three targeted drugs (tucatinib, trastuzumab, and capecitabine) along with radiation to the brain or spine for people whose HER2-positive breast cancer has spread to the lining of the brain or spinal cord. The goal is to see if this treatment is safe and effective.
Ottawa, OntarioAges 18 years+ - NCT06977893RecruitingPhase 3
Chemo and immunotherapy for HR+ breast cancer before surgery
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
HangzhouAges 18–75 - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Birmingham, AlabamaAges 18 years+ - NCT06671262RecruitingPhase 2
Immunotherapy plus radiation before breast cancer surgery
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
Hangzhou, ZhejiangAges 18–85 - NCT07718425Recruiting
Endoscopic mastectomy surgery study
This study tests a new, less invasive surgery called endoscopic mastectomy for women who need breast removal. It aims to see how well the surgery works, how the breast looks and feels afterward, and whether nipple sensation is preserved.
Ponderano, BIAges 18–75 - NCT04065321Recruiting
Blood test for tumor cells in certain early breast cancers
This trial looks at a blood test that may detect “circulating tumor cells” (cancer cells that can travel in the bloodstream) in people with a specific type of breast cancer. It may help doctors better track the disease and guide treatment for people whose tumors have certain hormone and growth-factor features.
Shenyang, LiaoningAges 18–60 - NCT04913064Recruiting
White button mushroom supplement for inflammation in high-risk breast cancer
This trial tests whether a white button mushroom powder supplement can lower inflammation in postmenopausal women who have a high risk of breast cancer. If it helps, it could improve early prevention strategies for people at higher risk.
Duarte, CaliforniaAges 21 years+
Hear when a new Inflammatory Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for inflammatory breast cancer?
- Yes. Clin2 currently lists 322 recruiting inflammatory breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a inflammatory breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a inflammatory breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.